Wockhardt receives USFDA approval for Imatinib Mesylate


Wockhardt has received final USFDA approval for 100 mg and 400 mg tablets of Imatinib Mesylate to market the same in US markets. The drug is used to treat many kinds of cancers and tumors. It is a generic version of Gleevec, marketed in USA and other countries by Novartis.

Imatinib stops the cancer cells from growing and is indicated for treating cancers like Leukemia and some gastro-intestinal tumors. According to market estimates, the product has sales potential of $ 707 million in the US. The product is being manufactured at a contract manufacturing facility, based near Hyderabad, India.

Company Profile : Wockhardt Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.